{"created":"2023-05-15T14:36:30.404098+00:00","id":47015,"links":{},"metadata":{"_buckets":{"deposit":"fb7eeab6-a52f-4ab8-814b-4e496f5ad792"},"_deposit":{"created_by":1,"id":"47015","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"47015"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00047015","sets":["1"]},"author_link":["469378","469379","469380"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"147","bibliographicPageStart":"146","bibliographicVolumeNumber":"16","bibliographic_titles":[{"bibliographic_title":"Hellenic Journal of Nuclear Medicine"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Treatment of recurrent prostate cancer (PC) after radical prostatectomy is based on the site of recurrent disease [1-3].  In a previous study, we showed that carbon-11 acetate positron emission tomography (AC PET) demonstrated marked uptake in 27/46 of PC patients in recurrence after radical prostatectomy\n(RP), while serum PSA was higher than 3.0ng/mL [4].  In the present paper we studied 11 patients with PC following RP, who had no clinical signs of recurrence, with PSA levels of>1.0 or 1.0-3.0ng/mL and under recent hormone treatment. ","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Hellenic Journal of Nuclear Medicine"}]},"item_8_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"http://nuclmed.web.auth.gr/magazine/eng/may13/index.htm"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://nuclmed.web.auth.gr/magazine/eng/may13/index.htm","subitem_relation_type_select":"URI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1790-5427","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"藤林, 康久"}],"nameIdentifiers":[{"nameIdentifier":"469378","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"et.al"}],"nameIdentifiers":[{"nameIdentifier":"469379","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"藤林 康久","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"469380","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Carbon-11-acetate positron emission tomography (PET), versus fluorine-18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of >1 to 3ng/mL.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Carbon-11-acetate positron emission tomography (PET), versus fluorine-18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of >1 to 3ng/mL."}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-12-25"},"publish_date":"2014-12-25","publish_status":"0","recid":"47015","relation_version_is_last":true,"title":["Carbon-11-acetate positron emission tomography (PET), versus fluorine-18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of >1 to 3ng/mL."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:44:55.310626+00:00"}